1. Home
  2. CYTK vs ICL Comparison

CYTK vs ICL Comparison

Compare CYTK & ICL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$59.89

Market Cap

7.6B

Sector

Health Care

ML Signal

N/A

Logo ICL Group Ltd.

ICL

ICL Group Ltd.

N/A

Current Price

$5.44

Market Cap

6.5B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
CYTK
ICL
Founded
1997
1968
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Agricultural Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
7.6B
6.5B
IPO Year
2004
2001

Fundamental Metrics

Financial Performance
Metric
CYTK
ICL
Price
$59.89
$5.44
Analyst Decision
Strong Buy
Hold
Analyst Count
18
2
Target Price
$87.56
$6.10
AVG Volume (30 Days)
1.7M
1.5M
Earning Date
05-25-2026
01-01-0001
Dividend Yield
N/A
3.38%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,368,000.00
N/A
Revenue This Year
$9.79
$6.04
Revenue Next Year
$302.66
$3.27
P/E Ratio
N/A
$31.41
Revenue Growth
N/A
N/A
52 Week Low
$29.31
$4.76
52 Week High
$70.98
$7.35

Technical Indicators

Market Signals
Indicator
CYTK
ICL
Relative Strength Index (RSI) 40.30 55.72
Support Level $59.25 $5.26
Resistance Level $65.93 $5.78
Average True Range (ATR) 2.65 0.11
MACD -0.32 0.03
Stochastic Oscillator 3.98 92.50

Price Performance

Historical Comparison
CYTK
ICL

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About ICL ICL Group Ltd.

ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and growing solutions. These segments all contribute to the company's development of agriculture, food, and engineered material products and services. Maximum revenue is generated from its phosphate solutions segment which uses phosphate commodity products, such as phosphate rock and fertilizer-grade phosphoric acid (green phosphoric acid), to produce specialty products. This segment also produces and markets phosphate-based fertilizers. Geographically, the company generates maximum revenue from Brazil followed by, the United States of America, China, United Kingdom, Germany, Spain, Israel, France, India, Netherlands, and other countries.

Share on Social Networks: